版本:
中国

BRIEF-Chemocentryx says its CCR2 inhibitor CCX872 shown to reduce liver fibrosis in nash models

Oct 18 Chemocentryx Inc

* chemocentryx's ccr2 inhibitor ccx872 shown to reduce liver fibrosis in nash models

* Chemocentryx inc - third-generation ccr2 inhibitor, ccx598, is poised to enter investigational new drug enabling studies in 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐